Repligen Corp. 10-K Summary: Fiscal Year Ended March 31, 2002
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended March 31, 2002, for Repligen Corporation, a biotechnology company based in Needham, Massachusetts. Repligen's strategy involves developing therapeutic products for pediatric diseases (autism, mitochondrial disease, immune disorders) while funding these efforts through the commercial sale of specialty pharmaceutical products, primarily Protein A for antibody purification and the recently approved diagnostic SecreFlo(TM).
Key Financial Metrics
| Metric | Fiscal 2002 | Fiscal 2001 |
|---|---|---|
| Total Revenue | $4.30 million | $2.26 million |
| Product Revenue | $4.30 million | $2.08 million |
| Net Loss | $(4.46) million | $(5.28) million |
| Net Loss Per Share | $(0.17) | $(0.20) |
| Research & Development Expense | $5.36 million | $5.79 million |
| Cash and Investments | $25.25 million | $30.30 million |
| Working Capital | $20.58 million | $24.40 million |
| Product Gross Margin | 54% | 33% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 91% year-over-year, driven by a 107% surge in Protein A product sales due to market growth in therapeutic antibodies and increased shipments to key customer Amersham.
- Margin Expansion: Product gross margin improved significantly from 33% to 54%, attributed to favorable product mix changes and manufacturing efficiencies.
- Expense Reduction: R&D expenses decreased 7% to $5.36 million, primarily due to reduced clinical trial and manufacturing costs for CTLA4-Ig and uridine programs.
- Investment Income: Investment income declined 46% to $1.12 million, reflecting lower interest rates and reduced average cash balances available for investment.
- Loss Narrowing: The net loss decreased by approximately $0.82 million compared to the prior year, despite continued heavy investment in clinical development.
Outlook, Risks, and Management Commentary
- Product Approvals: In April 2002 (post-fiscal year-end), the FDA approved SecreFlo(TM) (synthetic porcine secretin) for diagnosing pancreatic function and gastrinoma. This approval triggered a $1.25 million milestone payment and a requirement to issue approximately 696,000 shares of common stock to the licensor, ChiRhoClin.
- Clinical Pipeline:
- Secretin for Autism: Two Phase 3 clinical trials are underway for children aged 2.7 to 4.9 years.
- Uridine: A Phase 2 trial for mitochondrial disease is planned for 2002; research continues on its application for autism.
- CTLA4-Ig: A Phase 2 trial is ongoing for immune thrombocytopenic purpura (ITP).
- Liquidity and Capital Needs: Management expects to incur significantly higher costs in fiscal 2003 due to expanded clinical trials and the launch of SecreFlo(TM). While current cash resources are deemed sufficient for the next 24 months, the company may need to raise additional capital, which carries risks given the volatile biotechnology market.
- Legal Proceedings:
- Pro-Neuron Litigation: Pro-Neuron, Inc. sued to void Repligen's license agreement with UCSD regarding uridine. Repligen intends to defend vigorously; a loss could limit commercialization of uridine.
- BMS Patent Dispute: Repligen and the University of Michigan are litigating against Bristol-Myers Squibb to correct inventorship on patents covering CTLA4-Ig. Failure to obtain rights could restrict CTLA4-Ig commercialization.
- Facility Expansion: The company entered a 10-year lease for a new 25,000 sq. ft. headquarters in Waltham, MA, with relocation planned for the first quarter of fiscal 2003.
Investor Verification Checklist
- SecreFlo(TM) Commercialization: Verify the timeline and initial sales performance of the newly FDA-approved SecreFlo(TM) diagnostic product.
- Phase 3 Trial Results: Monitor the progress and preliminary data from the two Phase 3 trials for secretin in autism, as these are critical for future revenue potential.
- Legal Outcomes: Track the status of the Pro-Neuron lawsuit regarding the UCSD uridine license and the BMS patent dispute regarding CTLA4-Ig, as adverse rulings could eliminate key pipeline assets.
- Cash Burn Rate: Assess the impact of the $1.25 million milestone payment and the issuance of 696,000 shares on the company's liquidity and dilution.
- Customer Concentration: Note that 65% of revenue comes from foreign customers, with 85% of that foreign revenue attributable to just three customers (including Amersham).